Guardant Health Inc. experienced its biggest single-day stock drop Friday after releasing the results of a study analyzing its blood test for colorectal cancer.
The stock price of the Redwood City-based biotechnology company (Nasdaq: GH) closed Friday at $30.06 a share, a 27% decline from where it started the day. At one point, the stock was down 31%.
Before Guardant went public with the results of its test study on Thursday, analysts were expecting an 85% accuracy result, according to a Citigroup…
